Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly M Thompson

Showing results (71-80 of 180) with videos related to

Pageof 18
Sort By:
Risk Analysis : an Official Publication of the Society for Risk Analysis|December 23, 2006
Retrospective cost-effectiveness analyses for polio vaccination in the United StatesKimberly M Thompson, Radboud J Duintjer Tebbens
Expert Review of Vaccines|December 7, 2013
National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradicationKimberly M Thompson, Radboud J Duintjer Tebbens
Future Virology|December 28, 2020
How should we prepare for an outbreak of reintroduced live polioviruses?Kimberly M Thompson, Radboud J Duintjer Tebbens
Expert Review of Vaccines|May 4, 2012
Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessationKimberly M Thompson, Radboud J Duintjer Tebbens
The Journal of Infectious Diseases|October 16, 2014
Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessationRadboud J Duintjer Tebbens, Kimberly M Thompson
System Dynamics Review|September 23, 2021
Using integrated modeling to support the global eradication of vaccine-preventable diseasesRadboud J Duintjer Tebbens, Kimberly M Thompson
MDM Policy & Practice|October 6, 2018
Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine UseRadboud J Duintjer Tebbens, Kimberly M Thompson
Gates Open Research|March 14, 2022
Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication InitiativeKimberly M Thompson, Dominika A Kalkowska, Kamran Badizadegan
Risk Analysis : an Official Publication of the Society for Risk Analysis|February 16, 2021
No Role for Reintroducing OPV into the United States with Respect to Controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.]Kimberly M Thompson, Dominika A Kalkowska, Kamran Badizadegan
Vaccine|April 30, 2023
Outbreak management strategies for cocirculation of multiple poliovirus typesDominika A Kalkowska, Kamran Badizadegan, Kimberly M Thompson
Pageof 18

Showing results (71-80 of 180) with videos related to

Sort By:
Pageof 18
Risk Analysis : an Official Publication of the Society for Risk Analysis|December 23, 2006
Retrospective cost-effectiveness analyses for polio vaccination in the United StatesKimberly M Thompson, Radboud J Duintjer Tebbens
Expert Review of Vaccines|December 7, 2013
National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradicationKimberly M Thompson, Radboud J Duintjer Tebbens
Future Virology|December 28, 2020
How should we prepare for an outbreak of reintroduced live polioviruses?Kimberly M Thompson, Radboud J Duintjer Tebbens
Expert Review of Vaccines|May 4, 2012
Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessationKimberly M Thompson, Radboud J Duintjer Tebbens
The Journal of Infectious Diseases|October 16, 2014
Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessationRadboud J Duintjer Tebbens, Kimberly M Thompson
System Dynamics Review|September 23, 2021
Using integrated modeling to support the global eradication of vaccine-preventable diseasesRadboud J Duintjer Tebbens, Kimberly M Thompson
MDM Policy & Practice|October 6, 2018
Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine UseRadboud J Duintjer Tebbens, Kimberly M Thompson
Gates Open Research|March 14, 2022
Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication InitiativeKimberly M Thompson, Dominika A Kalkowska, Kamran Badizadegan
Risk Analysis : an Official Publication of the Society for Risk Analysis|February 16, 2021
No Role for Reintroducing OPV into the United States with Respect to Controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.]Kimberly M Thompson, Dominika A Kalkowska, Kamran Badizadegan
Vaccine|April 30, 2023
Outbreak management strategies for cocirculation of multiple poliovirus typesDominika A Kalkowska, Kamran Badizadegan, Kimberly M Thompson
Pageof 18